Remember me
Volume 18, Issue 7, July 2025, Pages 848-851
Author links open overlay panel, Section snippetsFunding Support and Author DisclosuresDr Dilsizian serves on the steering committee of Phase 3 multicenter study of I-124 evuzamitide, sponsored by Brigham and Women’s Hospital and Attralus, Inc; and is a consultant for GE HealthCare and CDL Nuclear LLC.
References (26)V. Dilsizian et al.Hybrid imaging for better diagnosis and treatment strategies—hope, hype and realityJACC Cardiovasc Imaging
(2024)
J Bourque et al.18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC Imaging Indications (ASNC I2) series expert consensus recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STSJACC Cardiovasc Imaging
(2024)
L Bang et al.Effect of alirocumab on carotid inflammation by [18F]FDG PET in patients with acute myocardial infarctionJACC Cardiovasc Imaging
(2024)
View full text© 2025 by the American College of Cardiology Foundation. Published by Elsevier.
Comments (0)